ARS Pharmaceuticals announced that the FDA posted briefing documents for the PADAC meeting to review their new drug application for neffy for the treatment of Type 1 allergic reactions.
AI Assistant
ARS PHARMACEUTICALS INC
2023
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.